BG Medicine Inc (BGMD)

[bertbex]

Email to the SEC: Yesterday (Wed, Feb. 10, 2021) I sent the following email to "[e-mail]" (The Boston Regional Office of the U.S. Securities and Exchange Commission"):

"Dear Sir or Madam,

if you request financial compensation for processing this request, please let me know before further processing!

I am a retail investor in BG Medicine (BGMD) based in Foxborough, MA (http://bg-medicine.com) whose chairman is Craig Jalbert (Verdolino & Lowey, PC Foxborough, MA) since July 26, 2018. On July 09, 2015 a 1 for 4 split was carried out, and on Sept. 16, 2015 the delisting from Nasdaq took place (https://www.otcmarkets.com/stock/BGMD/security). Since then, BG Medicine is traded on OTC pink sheets as "BGMD".

The big issue is (for retail investors like me) why since June 27, 2016 there have been no official publications any more from BGMD like operating business results? (see the last disclosures at https://www.otcmarkets.com/stock/BGMD/disclosure). Why they disclose at least no unaudited operating results? By the way, BGMD´s share price has risen again significantly since December 2020.

So is BGMD not violating against any laws by going dark intentionally?


I have collected the following information about BGMD:

- The answer below in this email trail from Craig Jalbert on Nov. 16, 2020: “…There is no reporting of any kind to anyone nor will there ever be.”

- The answer below in this email trail from Mary Jo Schindler Bailey on July 01, 2020 (her email address is shown when you click on “email us” at BGMD´s website “contact us”): "To recap BG’s status, on July 26, 2018, pursuant to Section 141(f) of the General Corporation Law of the State of Delaware, the directors of BG Medicine, Inc., appointed Craig R. Jalbert, as Chairman, Chief Executive Officer, President, Chief Financial Officer, Treasurer and Secretary of the Corporation, to serve in accordance with the company’s Bylaws, and to manage the company’s business affairs going forward. The former BG Board of Directors resigned at that time. The company continues to operate, as having entered in to several manufacturing and sales agreements with several partners. With that said, the company is limping along right now. There is no bankruptcy, and not much else to report at this time.”

- BGMD has withdrawn their new drug application on Dec. 23, 2015: https://www.globenewswire.com/news-release/2015/12/23/797949/0/en/BG-Medicine-Withdraws-510-k-Premarket-Notification-for-Proposed-Additional-Indication-for-the-BGM-Galectin-3-Test.html

- BGMD maybe paid back their debts: https://www.gurufocus.com/term/deb2equity/BGMD/Debt-to-Equity/BG%2BMedicine%2BInc

- BGMD has obviously a patent in processing: https://patents.google.com/patent/US20200033367A1/en

- BGMD obviously paid a scientist: "See at footnotes: "Dr. Cappola has received research funding from BG Medicine.": https://www.sciencedirect.com/science/article/abs/pii/S2213177919308005

- According to https://www.otcmarkets.com/stock/BGMD/security there might be still a major shareholder who owns 1,979,380 shares, because this number of shares results in the difference between 11,374,360 outstanding shares (Dec. 19, 2018) and float of 9,394,980 shares (Sept. 15, 2015). Perhaps this could be a reason for a dispute in how to lead the company? (More information about BGMD´s current share ownership is available at https://fintel.io/so/us/bgmd if still correct?)


I would be glad to get an answer from you.
With Best Regards

XXXX YYYYYYY
Address: zzz
Tel. mobile: zzz
Email: zzz"

(If I will get an answer from the SEC, I will publish it here on Investorshub)